United States Organ-On-Chip Market Size, Share & Trends Analysis Report By Organ Type (Heart on chip, Human on chip, Intestine on chip, Kidney on chip, Liver on chip, Lung on chip), By Applications (Drug Discovery, Toxicology Research, Physiological Model Developments), By End-User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Others) and Forecasts, 2026-2034

United States Organ-on-Chip Market Size and Trends

The United States Organ-On-Chip Market size was valued at USD 1.08 billion in 2025 and is projected to grow from USD 1.28 billion in 2026 to reach USD 4.93 billion by 2034, growing at a CAGR of 18.37% during the forecast period 2026–2034.

In the past few years, there has been a surging concern regarding the welfare of animals used as models during drug testing and research, which has, in turn, increased the demand for alternative testing methods. This is anticipated to drive the United States organ-on-chip market. Moreover, organ-on-chip models are also used in predictive toxicology for environmental testing, which is done to meet stringent environmental regulations, thereby creating opportunities for regional market expansion.

United States Organ-on-Chip Market Growth Factors

Rising Demand for Alternative Testing Methods

The increasing ethical concerns regarding animal testing have significantly fueled the demand for alternative testing methods in the United States, positioning the Organ-On-Chip (OOC) market for rapid growth. Traditional animal testing methods are under scrutiny due to their high costs, time consumption, and ethical implications. According to a report by the National Institutes of Health (NIH), over 90% of drugs that pass animal testing fail in human clinical trials due to differences in physiology between species. This disparity has driven researchers and pharmaceutical companies to seek more reliable and ethical alternatives.

The OOC technology, which mimics human organ physiology on a microchip, offers a promising solution by providing more accurate predictions of human responses to drugs. The U.S. Food and Drug Administration (FDA) has also recognized the potential of OOC technology, with initiatives like the "FDA Predictive Toxicology Roadmap" that encourage the adoption of such innovative tools. As regulatory bodies and pharmaceutical companies increasingly invest in OOC technology, the market is expected to witness substantial growth in the coming years.

United States Organ-on-Chip Market Restraint

Regulatory Challenges and Standardization Issues

One of the significant restraints facing the U.S. Organ-On-Chip market is the lack of standardized regulatory frameworks and guidelines. As OOC technology is relatively new, regulatory bodies like the U.S. Food and Drug Administration (FDA) are still in the process of establishing clear guidelines for its use in drug testing and other applications. This lack of standardization can lead to uncertainties for companies and researchers, potentially delaying the adoption of OOC technology.

Furthermore, the absence of universally accepted benchmarks for evaluating the performance and reliability of OOC devices adds to the challenges. Companies may face difficulties in gaining regulatory approval for their products, which could slow down market growth. As the technology evolves, there will be a need for more defined regulatory pathways to ensure that OOC systems meet safety and efficacy standards, which could mitigate this restraint in the future.

United States Organ-on-Chip Market Opportunities

Expansion into Predictive Toxicology for Environmental Testing

A significant market opportunity for Organ-On-Chip (OOC) technology in the U.S. lies in its expansion into predictive toxicology for environmental testing. As environmental regulations become increasingly stringent, there is a growing need for accurate and reliable methods to assess the toxicological impact of chemicals and pollutants on human health. OOC devices can simulate human organ responses to various environmental toxins, providing more precise data than traditional methods.

This application is particularly valuable for industries such as chemicals, agriculture, and cosmetics, where understanding the long-term effects of exposure to specific substances is critical. The Environmental Protection Agency (EPA) in the U.S. has been exploring the use of alternative testing methods, including OOC technology, to meet regulatory requirements. As industries and regulatory bodies seek to enhance environmental safety, the adoption of OOC in predictive toxicology is expected to rise, creating a new avenue for market growth.

United States Organ-On-Chip Market Segmental Analysis

By Organ Type Insights

In terms of organ type, the liver-on-chip segment is expected to hold a prominent position in the United States organ-on-chip market. Liver-on-chip platforms can reproduce selected liver functions, cellular interactions, and physiological conditions within controlled microfluidic environments. These capabilities make them useful for evaluating drug metabolism, compound responses, and potential toxicity during preclinical research.

The segment is benefiting from the strong pharmaceutical and biotechnology ecosystem in the U.S., along with increasing interest in more human-relevant testing models. Researchers and drug developers are using advanced tissue models to complement conventional laboratory approaches and improve the understanding of how therapeutic candidates may behave in human tissues.

Other organ types, including heart on chip, human on chip, intestine on chip, kidney on chip, and lung on chip, are also gaining importance. Heart-on-chip models can support cardiovascular research and investigation of drug-induced effects, while kidney-on-chip platforms are useful for studying renal function and nephrotoxicity. Intestine- and lung-on-chip systems can reproduce selected tissue barriers and physiological responses. Human-on-chip platforms further expand the field by enabling researchers to examine interactions between multiple organ systems.

Request Customizationto receive a tailored report.

By Applications Insights

Based on application, drug discovery is expected to remain a leading application area in the United States organ-on-chip market. These platforms enable researchers to examine candidate compounds in controlled biological environments and investigate drug responses during preclinical development.

The increasing focus on improving the predictability of preclinical research is supporting the adoption of organ-on-chip technologies across pharmaceutical and biotechnology companies. The systems can reproduce selected physiological conditions, tissue interactions, and dynamic biological processes that are difficult to fully represent using conventional cell cultures. The U.S. pharmaceutical research ecosystem and continued development of microfluidics, tissue engineering, and advanced cellular models are further supporting adoption.

Toxicology research is another important application, particularly for assessing potential adverse effects of drug candidates and other substances. Liver, kidney, lung, and heart models can provide organ-specific environments for evaluating biological responses and identifying potential safety concerns at earlier stages.

Meanwhile, physiological model development is gaining traction as researchers develop increasingly sophisticated platforms for studying disease mechanisms, tissue behavior, therapeutic responses, and personalized medicine. The integration of multiple biological components is also creating opportunities for more comprehensive human physiology models.

By End-User Insights

By end-user, the United States organ-on-chip market is segmented into Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others. The Pharmaceutical and Biotechnology Companies segment is expected to represent a significant area of demand as drug developers increasingly explore human-relevant platforms for preclinical research.

These companies can use organ-on-chip systems for candidate screening, drug-response analysis, toxicity evaluation, disease modeling, and investigation of biological mechanisms. The technology can support pharmaceutical development by providing controlled environments that more closely represent selected aspects of human physiology than conventional laboratory models.

Academic and Research Institutes represent another important end-user group. Universities and research organizations are contributing to advancements in microfluidics, tissue engineering, cellular biology, disease modeling, and multi-organ systems. Their research activities are helping expand the capabilities of organ-on-chip platforms and identify new applications.

The Others category includes specialized research organizations, technology developers, and other biomedical users. As collaborations between academia, pharmaceutical companies, biotechnology firms, and technology providers increase, these users are expected to contribute to the broader development and commercialization of organ-on-chip technologies in the United States.

Speak to an Analystto discuss market opportunities.

United States Organ-on-Chip Market Regional Analysis

The United States is a leading hub in the global Organ-On-Chip (OOC) market, driven by its advanced research infrastructure, significant investment in biotechnology, and supportive regulatory environment. Key regions such as Massachusetts, California, and New York are at the forefront of OOC development, with Massachusetts alone contributing to over 20% of all U.S. biotech venture capital investments. The concentration of top-tier research institutions, including Harvard University and the Massachusetts Institute of Technology (MIT), amongst others, fosters innovation in OOC technology.

For instance, in June 2024, a significant advancement in the study of women's reproductive health was made by a team of scientists from Harvard Medical School, Boston Children's Hospital, the Wyss Institute for Biologically Inspired Engineering at Harvard University, and the University of California, Davis. They have successfully created a laboratory model known as a cervix-on-a-chip, which accurately mimics the structure and functionality of the human cervix.

Similarly, in October 2023, the Terasaki Institute for Biomedical Innovation (TIBI) created a new technology called an organ-on-a-chip, which can measure electrical resistance across endothelial walls. This chip contained carbon-based electrodes that were screen-printed onto a multi-layered microfluidic chip. The chip was created using a simple and cost-effective process. Furthermore, the National Institute of Standards and Technology (NIST) is currently in the process of developing an innovative 'heart-on-a-chip.' The device replicates the cellular connections found in a human heart. Consequently, all these advancements are expected to augment the United States organ-on-chip market growth.

List of Key and Emerging Players in United States Organ-On-Chip Market

• AxoSim Inc.
• BiomimX SRL
• CN Bio
• Emulate Inc.
• Hurel Corporation
• InSphero AG
• MIMETAS BV Nortis Inc.
• Tara Biosystems Inc.
• TissUse GmbH
• Others